life science investing Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
life science investing Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
life science investing Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
life science investing Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
life science investing Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
Nuvau Announces Voting Results of Its Annual and Special Meeting of Shareholders and Announces the Appointment of Steven Bowles as Chair of the Board
SAGA Metals Appoints Accomplished Mining Executive Peter Hogendoorn to Board of Advisors and Engages Xander Capital Partners
Blue Lagoon Announces Major Steps Toward Production: Fully Funded, Government Inspections Passed, and Water Treatment Plant Completed
